U.S. health regulators are taking their closest look in more than three years at the idea of incorporating cannabinoids into dietary supplements.
But hopes are dim that Tuesday’s daylong review by the U.S. Food and Drug Administration’s Science Board will finally deliver a path to treating CBD like other dietary supplements – regulated but sold without prescriptions.
ADVERTISEMENT
“It’s hard to get too excited about anything anymore,” said Vince Sanders, a CBD manufacturer and retailer in Missouri who traveled to Maryland in 2019 to attend the FDA’s first CBD hearing and has since seen the agency take little action to guide how CBD can be made outside pharmaceutical channels.
Tuesday’s meeting is an informational discussion by the FDA’s Science Board, an advisory panel made up of outside nutrition and drug-safety experts.
The panel meets intermittently, and the virtual daylong discussion Tuesday focuses on “challenges in evaluating the safety of
Read full article on Marijuana Business Daily
